ANGUSTA® (misoprostol 25 μg):
An approved oral misoprostol treatment for the induction of labour
ANGUSTA® is an approved oral misoprostol treatment for the induction of labour1. ANGUSTA® is effective at inducing labour2 and clinical data supports the use of low dose oral misoprostol for the induction of labour3-6. ANGUSTA® has already been used for the induction of >100,000 women7.
When induction is needed, support her choice with the convenience and non-invasiveness of an oral induction.
women who received oral misoprostol would use it again for future inductions (n=302)4
of women who received oral misoprostol would have preferred a Foley catheter (n=273)8
of women expressed a preference for an oral induction agent (n=741)5
Previous clinical trials of oral misoprostol have shown it to be:
of women had a vaginal delivery
of women gave birth within 24 hours
of women gave birth within 48 hours
The adverse event profile has been assessed in a compassionate use programme including >29,000 women.1
If required during labour, administration of oxytocin can start 4 hours after the last dose of ANGUSTA®.1 Breastfeeding can start 4 hours after the last dose of ANGUSTA®.1
Adverse events may include nausea, vomiting, meconium stain, postpartum
haemorrhage, diarrhoea, uterine hyperstimulation, chills, pyrexia, low Apgar score and abnormal foetal heart rate.
For a full list of adverse reactions, details on precautions for use and contraindications, please refer to the ANGUSTA® Summary of Product Characteristics.
ANGUSTA® comes as ready-to-use oral tablets of 25 μg misoprostol.1 Two dosing options enable individualised treatment plans according to your hospital practice.1
The recommended maximum dose is 200 μg (8 tablets) over a period of 24 hours.1
1 tablet every 2 hours
2 tablets every 4 hours
Adverse events should be reported to your local regulatory agency, or in the UK Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to directly to Norgine Ltd by emailing GPharmacovigilance@norgine.com. By reporting side effects, you can help provide more information on this medicine.